FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washingto	on. D.C	. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
--

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  SASSINE ANDY  (Last) (First) (Middle)  C/O ARCTURUS THERAPEUTICS HOLDINGS INC.  10628 SCIENCE CENTER DRIVE, SUITE 250  (Street)  SAN DIEGO CA 92121				3 1	2. Issuer Name and Ticker or Trading Symbol Arcturus Therapeutics Holdings Inc. [ ARCT ]  3. Date of Earliest Transaction (Month/Day/Year) 12/09/2022  4. If Amendment, Date of Original Filed (Month/Day/Year)						[Cher X X X A A A A A A A A A A A A A A A A	Relationship of Reporting Person(s) to Issuer leck all applicable)  X Director 10% Owner  X Officer (give title Other (specify below)  Chief Financial Officer  Individual or Joint/Group Filing (Check Applicable e)  X Form filed by One Reporting Person  Form filed by More than One Reporting			ner pecify
(City)	(S	state)	(Zip)									Person			
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
Date				2. Transact Date Month/Day	Execution Date,		Date,	3. Transaction Code (Ins 8)	n Disposed			Beneficial Owned Fo	Form (D) or	orm: Direct ) or Indirect (Instr. 4)	7. Nature of ndirect Beneficial Ownership
				Code V			Amount	(A) or (D)	Price	Reported Transactio (Instr. 3 ar			Instr. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	cise (Month/Day/Year) ve	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title an of Securit Underlyin Derivative (Instr. 3 a	g Security	Derivative Security	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(9)	
Employee Stock Option (right to buy)	\$16.92	12/09/2022		A		125,000 <sup>(1)</sup>		(2)	12/09/2032	Common Stock	125,000	\$0.00	125,000	D	

## **Explanation of Responses:**

- 1. Represents options to purchase shares of common stock approved by the Board of Directors on December 9, 2022 pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as
- 2. The shares underlying this option vest 25% on December 9, 2023, the first anniversary of the date this award was approved by the Board of Directors, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.

/s/ Ilan Katz, attorney-in-fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.